一、2020一季度，清華大學免疫學與醫(yī)學院；清華大學生命科學學院聯(lián)合發(fā)表標題為：The colonic macrophage transcription factor RBP-J orchestrates intestinal immunity against bacterial pathogens的文章到JEM；

二、用invigentech（英克)INVI DNA RNA Transfection Reagent轉(zhuǎn)染試劑；

三、成功轉(zhuǎn)染BMDMs細胞(小鼠骨髓來源的巨噬細胞)發(fā)表文章見刊；

四、文章簡介：結(jié)腸巨噬細胞轉(zhuǎn)錄因子RBP-J協(xié)調(diào)腸道對細菌的免疫病原體研究.

五、文章部分內(nèi)容見下：

RNA-mediated interference

siRNA specifically targeting mouse Cebpb and nontargeting control siRNA were purchased from GenePharma Company. siRNA was transfected into BMDMs using INVI DNA RNA Transfection Reagent according to the manufacturer’s in structions (Invigentech). Cells were used 48 h after transfection. 

Figure S2. RBP-J KO mice display normal activation of ILC3 and humoral immune responses during the adaptive immune response phase against C.

rodentium infection. (A) 6–8-wk-old WT and RBP-J KO mice were orally inoculated with 2 × 109 CFUs of C. rodentium, and colons were harvested at the

indicated time points p.i. qPCR analysis of the indicated mRNAs in colon tissues is shown. Data are pooled from two independent experiments; n = 3 in each

group. (B) qPCR of Rbpj in sorted LP CD4+ T cells from uninfected mice. Data are pooled from two independent experiments; n = 3 in each group. (C–H)

Representative FACS plots of colonic LP ILC3 (CD45midCD3−Thy-1+), IL-22–producing ILC3 and Th17 cells (CD3+CD4+RORγt+) at day 7 p.i. (C, E, and G) and

cumulative data (D, F, and H). Data are pooled from two independent experiments; n ≥ 3 in each group. (I and J) Serum anti–C. rodentium immunoglobulin G2b

(IgG2b) and IgG2c titers (I) and fecal secretory IgA (sIgA) titers (J) at day 12 p.i. were measured by ELISA. Data are pooled from two independent experiments;

n = 3 in each group. Data are shown as mean ± SEM; two-tailed Student’s unpaired t test. n.s., not significant; SSC-A, side scatter area.

invigentech（英克）INVI DNA轉(zhuǎn)染試劑信息如下